SCHEMBL2200809

SCHEMBL2200809

CCC1OC(=C2C(=O)Nc3ccccc32)c2cnc(Cl)c(Cl)c21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.34
NPC1 O15118 2/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
GAA P10253 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
KDR P35968 1/20 0.33
MAPK1 P28482 1/20 0.33
CCKBR P32239 1/20 0.32
GSK3B P49841 2/20 0.32
ALK Q9UM73 1/20 0.32
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
PDGFRA P16234 1/20 0.31
FER P16591 1/20 0.31
LTK P29376 1/20 0.31
CDK8 P49336 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2200808 1.00 KMT2A (0.34) KMT2ANPC1MAPTPOLBRAB9A
SCHEMBL2199233 0.86 TOP1 (0.34) KMT2AMAPTKDRLRRK2MEN1
SCHEMBL2199234 0.86 TOP1 (0.34) KMT2AMAPTKDRLRRK2MEN1
SCHEMBL2200045 0.82 MAPT (0.33) KMT2ANPC1MAPTPOLBRAB9A
SCHEMBL2200047 0.82 MAPT (0.33) KMT2ANPC1MAPTPOLBRAB9A
SCHEMBL2196773 0.81 MAPK1 (0.37) KMT2ANPC1MAPTPOLBRAB9A
SCHEMBL2196779 0.81 MAPK1 (0.37) KMT2ANPC1MAPTPOLBRAB9A
SCHEMBL12247865 0.78 IDO1 (0.37) KMT2ANPC1MAPTPOLBRAB9A
SCHEMBL2197821 0.78 PGR (0.35) KMT2AKDRALKLRRK2MEN1
SCHEMBL2197816 0.78 PGR (0.35) KMT2AKDRALKLRRK2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455535-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2013-06-04 US disclosed
US-20110257238-A1 Heteroaryl Dihydroindolones as Kinase Inhibitors ALLERGAN, INC. (US) 2011-10-20 US disclosed
US-7977351-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2011-07-12 US disclosed
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS ALLERGAN, INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257238-A1 Heteroaryl Dihydroindolones as Kinase Inhibitors REN, JAK2, ABL1 KMT2A 442/4885NPC1 4033/4885MAPT 4415/4885
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS REN, JAK2, ABL1 KMT2A 442/4885NPC1 4033/4885MAPT 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.